How should rituximab be used to treat Kinsbourne (opsoclonus‑myoclonus‑ataxia) syndrome in children?

Rituximab for Kinsbourne (Opsoclonus-Myoclonus-Ataxia) Syndrome in Children

Rituximab should be used as part of upfront multimodal immunotherapy combining dexamethasone (or ACTH), intravenous immunoglobulin (IVIG), and rituximab for children with opsoclonus-myoclonus-ataxia syndrome, rather than being reserved only for refractory cases.

Treatment Algorithm

First-Line Multimodal Immunotherapy

The most effective approach based on recent evidence combines three agents simultaneously 1, 2, 3:

Rituximab dosing:

• Standard dose: 375 mg/m² weekly for 4 consecutive weeks (total 1500 mg/m²)
• Reduced dose: 300 mg/m² weekly for 4 consecutive weeks (total 1200 mg/m²) 2
  • Both doses achieve equivalent B-cell depletion (≥95% in CSF) and clinical response (≥76% reduction in motor severity)
  • Reduced dosing may minimize risk of chronic hypogammaglobulinemia while maintaining efficacy

Combined with:

• Pulse dexamethasone OR ACTH (adrenocorticotropic hormone)
• IVIG at 2 g/kg per cycle

This combination achieves:

• 69-76% reduction in motor severity scores 2, 3
• 94% reduction in CSF B-cell frequencies 3
• Normalization of CSF oligoclonal bands 3
• Better long-term outcomes with fewer relapses 1, 4

When Rituximab is Unavailable

If rituximab cannot be obtained, use dexamethasone pulses plus IVIG as an alternative 5:

• Monthly dexamethasone pulses
• IVIG 2 g/kg monthly
• This achieves reasonable control but may require longer treatment duration

Treatment for Relapse

For patients who relapse after initial full-dose rituximab therapy 6:

• Single additional dose of rituximab 375 mg/m² may be sufficient
• No need to repeat the full 4-week course
• Monitor for sustained remission over 2+ years

Critical Timing Considerations

Early intervention is essential 4:

• Addition of second-line therapy (rituximab or cyclophosphamide) within 6 months of disease onset significantly improves prognosis (OR=11.64, P=0.030)
• Delayed treatment increases risk of permanent neurological sequelae
• The mean duration from onset to therapy initiation should be <2 months 1

Tumor Evaluation

Before initiating treatment 7:

• Perform MIBG scan to identify neuroblastoma, ganglioneuroblastoma, or ganglioneuroma
• Consider CT chest/abdomen/pelvis with IV contrast if MIBG unavailable
• Approximately 50% of pediatric OMAS cases are paraneoplastic 8, 4
• Tumor-associated cases have lower relapse rates (OR=0.19, P=0.041) 4

Monitoring and Safety

FDA-approved pediatric use 9:

• Rituximab is approved for pediatric patients ≥6 months for B-cell malignancies
• Safety established in children as young as 6 months
• Higher infection rates in children <3 years require vigilant monitoring

Key monitoring parameters:

• B-cell counts (expect ≥95% depletion in CSF and ≥76% in blood) 2, 3
• Serum immunoglobulins (IgM typically depletes 64-73%) 2
• Watch for chronic hypogammaglobulinemia and B lymphopenia
• B-cell repopulation typically occurs within 6 months 9

Contraindications and precautions:

• Defer live vaccines during treatment 9
• Screen for latent tuberculosis before starting (case report of TB reactivation during treatment) 5
• Monitor for infusion reactions during first dose

Common Pitfalls to Avoid

1. Delaying rituximab until after steroid failure: The evidence shows upfront multimodal therapy is superior to sequential monotherapy 1, 3

2. Using steroids or IVIG alone: Partial response to dexamethasone ± IVIG indicates ongoing neuroinflammation requiring prompt escalation 3

3. Repeating full 4-week rituximab courses for relapse: A single additional dose may suffice 6

4. Missing the 6-month window: Second-line therapy added after 6 months has worse outcomes 4

Expected Outcomes

With multimodal immunotherapy including rituximab 1, 8:

• 83% achieve remission without permanent neurological sequelae
• 28% relapse rate (lower in tumor-associated cases)
• 57% have some neurological sequelae at follow-up
• Mitchell-Pike scale scores improve to median 0.5-1.0 at final follow-up

The combination of dexamethasone, IVIG, and rituximab represents the most effective evidence-based approach for reducing relapses and preventing permanent neurological damage in pediatric opsoclonus-myoclonus-ataxia syndrome 1, 2, 3.